价格

PHARMAKO BIOTECHNOLOGIES PTY LIMITED

U 2 2 Aquatic Dr, Frenchs Forest, New South Wales, 澳大利亚

别名:

pharmako biotechnologies pty ltd

概览

试验阶段分布

阶段

试验数

占比

不适用

100.0%

试验状态分布

已完成

100.0%

药物批准

按机构分类的批准

TGA

Therapeutic Goods Administration

药物批准

近期批准

Levagen+ 300mg Capsules - Active (463876)

TGA

2024-10-08

Levagen+ 300mg Capsules - Active (463876)

TGA

2024-10-08

Berberine (Positive Control ) 188mg Capsule (460811)

TGA

2024-08-27

BioBerb (LipiSperse Berberine) 188mg Capsule (460810)

TGA

2024-08-27

Berberine (Positive Control ) 188mg Capsule (460811)

TGA

2024-08-27

BioBerb (LipiSperse Berberine) 188mg Capsule (460810)

TGA

2024-08-27

Positive Control GLM Capsule (455305)

TGA

2024-07-15

Positive Control GLM Capsule (455305)

TGA

2024-07-15

AquaCelle(R) GLM Capsule (454933)

TGA

2024-07-10

AquaCelle(R) GLM Capsule (454933)

TGA

2024-07-10

资讯

暂无资讯文章

返回机构列表

PHARMAKO BIOTECHNOLOGIES PTY LIMITED

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（1）

A study to evaluate the plasma absorption of 4 (four) EPA/DHA formulations on increasingOmega-3 fatty acid concentration in healthy participants over an 8-week period.

药物批准

按机构分类的批准

近期批准

资讯